DelveInsight has launched a new report on “Chronic Plaque Psoriasis – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Chronic Plaque Psoriasis Market Report:
- According to Delveinsight’s estimates, the total prevalent population of psoriasis in the seven major markets was 15,450,712 cases in 2020.
- According to the World Psoriasis Day Consortium, 125 million people worldwide, i.e., 2–3% of the total population, have psoriasis.
- As per Dogra and Mahajan, Chronic plaque-type psoriasis is the most common morphologic presentation of psoriasis, accounting for more than 90% of all cases.
- As per a study by Lui and Elston, In the United States, 1-2% of the population has plaque psoriasis.
Key benefits of the report:
- Chronic Plaque Psoriasis market report covers a descriptive overview and comprehensive insight of the Chronic Plaque Psoriasis Epidemiology and Chronic Plaque Psoriasis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Chronic Plaque Psoriasis market report provides insights on the current and emerging therapies.
- Chronic Plaque Psoriasis market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Chronic Plaque Psoriasis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Plaque Psoriasis market.
Chronic Plaque Psoriasis Overview
Psoriasis is recognized as the most prevalent immune-mediated inflammatory disease, involving skin and joints and is associated with abnormalities of other systems. Even though the condition is not life-threatening, it is difficult to treat and response rates vary widely.
Psoriasis has both pediatric and adult-onset, with the former accounting for more number of cases. Plaques vary in terms of variable morphology, distribution, and severity. Psoriatic patients are frequently categorized into two groups: mild or moderate-to-severe psoriasis, depending on the clinical severity of the lesions, the percentage of affected body surface area, and patient quality of life.
There are different clinical types of psoriasis, the most common of which is plaque psoriasis. Plaque psoriasis typically presents with large oval-circular plaques over the scalp, trunk, and extensor body surface. The plaques have an extensive amount of scaling due to the hyperproliferation of the epidermal cells.
Chronic Plaque Psoriasis Market
The dynamics of the Chronic Plaque Psoriasis market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as UCB, Bristol Myers Squibb, Merck, Dermavant Sciences, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, and others during the forecasted period 2019-2032.
Chronic Plaque Psoriasis Pipeline Therapies and Key Companies
- Bimekizumab: UCB
- Tapinarof: Dermavant Sciences
- Deucravacitinib: Bristol Myers Squibb
- ARQ-151: Arcutis Biotherapeutics
- BI 730357: Boehringer Ingelheim
- Brepocitinib (PF-06700841), PF-06826647: Pfizer
- Sonelokimab: Merck
- And others.
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Chronic Plaque Psoriasis Patient Share (%) Overview at a Glance
5. Chronic Plaque Psoriasis Market Overview at a Glance
6. Chronic Plaque Psoriasis Disease Background and Overview
7. Chronic Plaque Psoriasis Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Plaque Psoriasis
9. Chronic Plaque Psoriasis Current Treatment and Medical Practices
10. Unmet Needs
11. Chronic Plaque Psoriasis Emerging Therapies
12. Chronic Plaque Psoriasis Market Outlook
13. Country-Wise Chronic Plaque Psoriasis Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Chronic Plaque Psoriasis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Request a sample report @https://www.delveinsight.com/sample-request/chronic-plaque-psoriasis-market
Related Reports:
Chronic Plaque Psoriasis Pipeline
“Chronic Plaque Psoriasis Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights into present clinical development scenarios and growth prospects across the Chronic Plaque Psoriasis market. A detailed picture of the Chronic Plaque Psoriasis pipeline landscape is provided, which includes the disease overview and Chronic Plaque Psoriasis treatment guidelines.
Chronic Plaque Psoriasis Epidemiology
DelveInsight’s ‘Chronic Plaque Psoriasis Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Chronic Plaque Psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/